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Streptococcus agalactiae clones infecting humans
were selected and fixed through the extensive
use of tetracycline
Violette Da Cunha1,2,3,*, Mark R. Davies4,5,*, Pierre-Emmanuel Douarre1,2, Isabelle Rosinski-Chupin1,2,
Immaculada Margarit6, Sebastien Spinali7, Tim Perkins6, Pierre Lechat3, Nicolas Dmytruk7, Elisabeth Sauvage1,2,
Laurence Ma8, Benedetta Romi6, Magali Tichit8, Maria-Jose´ Lopez-Sanchez1,2, Ste´phane Descorps-Declere3,
Erika Souche3, Carmen Buchrieser2,9, Patrick Trieu-Cuot1,10, Ivan Moszer3, Dominique Clermont11,
Domenico Maione6, Christiane Bouchier8, David J. McMillan12,13, Julian Parkhill4, John L. Telford6,
Gordan Dougan4, Mark J. Walker5, The DEVANI Consortiumz, Matthew T. G. Holden4,w,
Claire Poyart1,7,14,15 & Philippe Glaser1,2,3
Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal of the digestive and
genitourinary tracts of humans that emerged as the leading cause of bacterial neonatal
infections in Europe and North America during the 1960s. Due to the lack of epidemiological
and genomic data, the reasons for this emergence are unknown. Here we show by com-
parative genome analysis and phylogenetic reconstruction of 229 isolates that the rise of
human GBS infections corresponds to the selection and worldwide dissemination of only a
few clones. The parallel expansion of the clones is preceded by the insertion of integrative
and conjugative elements conferring tetracycline resistance (TcR). Thus, we propose that the
use of tetracycline from 1948 onwards led in humans to the complete replacement of a
diverse GBS population by only few TcR clones particularly well adapted to their host, causing
the observed emergence of GBS diseases in neonates.
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S
treptococcus agalactiae, or Group B streptococcus (GBS)
generate considerable neonatal morbidity and mortality
worldwide1,2. In the 1960s, it became the leading cause of
neonatal infections in the US and in Europe. The first
descriptions of the increase of GBS disease were reported in
1964 as between December 1961 to June 1963 GBS was described
as the most frequent cause of neonatal sepsis at the Boston city
hospital3 and in 1965, when Kexel and Scho¨nbohm4 reported
three independent cases of meningitis caused by GBS at the
Children’s Clinic of the University of Bonn in Germany.
However, in humans S. agalactiae is primarily a commensal of
the digestive and urinary tracts, colonizing about 15–30% of
healthy adults1. Surprisingly, multi-locus sequence typing
(MLST) of GBS isolated from different countries showed that
most human carriage and clinical isolates cluster into only five
major clonal complexes (CC) (CC1, CC10, CC17, CC19 and
CC23)5 (Table 1). Among those, CC17 strains are considered
‘hypervirulent’ as they are responsible for the vast majority of the
meningitis among neonates, and for more than 80% of the late-
onset disease cases appearing after 7 days of life5,6. In contrast,
strains responsible for early-onset disease, appearing before the
6th day of life, belong to all five major CCs. A sixth CC, CC26 is
common in African countries7. In addition to causing disease in
humans, GBS is also a veterinary pathogen, causing bovine
mastitis8. Distinct from human isolates, the majority of bovine
isolates belongs to the CC67, a CC for which no human strains
have been described9. Phylogenetic analysis of 238 isolates of
human and bovine origin based on the sequences of 15 genes
revealed that CC17 strains represent a homogeneous group of
strains of recent origin9. The expansion of CC17 strains was
suggested to have contributed to the emergence of GBS infections.
However, until now, the events responsible for this expansion and
the emergence of GBS neonatal infections were unknown.
Here we set out to examine GBS evolution and the rise of
neonatal GBS infections. We sequence the genomes of 229 strains
isolated between 1953 and 2011 spanning four continents. By
combining phylogenetic analyses and the analysis of antibiotic
resistance markers, we show that all six human associated CCs
have a recent origin and that the observed homogeneity of CC17
strains results from a low rate of recombination relative to the
other CCs. Most importantly, we show that the emergence of GBS
diseases is associated with the replacement of the bacterial
population by a limited number of tetracycline resistant (TcR)
clones.
Results
Genome-based phylogeny reveals the expansion of a few clones.
The sequence of 216 GBS genomes of carriage and invasive
isolates selected to represent the known diversity of the human
GBS population based on MLST studies and of 13 isolates of
animal origin was determined. Single-nucleotide polymorphisms
(SNPs) were identified by mapping the sequence reads against the
genome sequence of a representative ST19 serotype III strain,
RBH11. This strain belongs to the dominant CC19 clone that has
been shown to display lower levels of polymorphism with strains
from other CCs10. In total, we identified 40,898 SNPs sites among
1,384,073 interrogated bases unambiguously mapped in the 229
genomes. Using maximum likelihood phylogenetic methods on
SNPs in the core chromosome, we determined that 97% of the
216 human isolates clustered into six well-resolved lineages that
correspond to the six major human CCs (Fig. 1a) as defined by
MLST (Table 1). The average polymorphism between lineages is
0.52% (ranging from 0.36 to 0.65%). Strikingly, we observed that
within each CC, one or two dominant clones showing limited
polymorphisms are present, representing 83% of all isolates. Such
a signature is indicative of an evolutionary bottleneck, which has
resulted in a recent reduction in population size and expansion of
positively selected clones.
GBS CCs except for CC17 show a high rate of recombination.
Based on the comparison of eight GBS genome sequences, we
previously showed that the recombination of large chromosomal
segments is a major contributor to the genomic diversification of
GBS10. Indeed, based on the SNP distribution, here we identified
evidence of recombination events encompassing all parts of the
core genome (Supplementary Fig. 1), thus distorting the true
phylogenetic relationships between GBS lineages. Recombination
within each single CC was extensive involving 47% of the genome
in CC1, 44% in CC10, 24% in CC19, 42% in CC23 and 19% in
CC26 strains but was surprisingly low in CC17, with only 3%
(Fig. 2 and Table 2). Most recombination events included genetic
determinants for known surface antigens, such as genes encoding
the capsular polysaccharide biosynthesis proteins, the major
antigenic protein Rib/Alp, the R5 protein, the serine-rich protein
and the pili (Table 2), which modulate host–cell interactions11. It
is therefore likely that immune pressure is a major driving force
in the genome diversification of human GBS.
Specific GBS clones expanded in the mid-20th century. To non-
ambiguously reconstruct the evolutionary history of the six GBS
lineages, we performed evolutionary studies separately for each
CC after mapping the sequencing reads against a representative
strain of the CC and filtering out the recombined regions (Figs 3
and 4, Supplementary Figs 2–5, and Table 2). This showed that
strains of each of the six CCs acquired only a very small number
Table 1 | Summary of global multi-locus sequence typing studies*.
Studyw Originz Clinical originy Number of
isolates
CC1 (ST1)|| CC10z CC17 CC19 (ST19, 28)|| CC23 CC26 Other
Jones5 World Ca, Ninv, Ainv 152 16% (14%) 18% 30% 17% (13%–2%) 12% 2% 5%
Luan55 Sweden (1988–1997) Ninv, Ainv 158 15% (9%) 13% 24% 29% (16%–1%) 14% 0 4%
Manning56 Canada Alberta (1993–2002) Ca, Ninv 413 23% (19%) 14% 16% 20% (19%–NA) 22% NA 5%
Bohnsack57 USA (1995–1999) Ca, Ninv 899 16% (15%) 9% 13% 17% (12%–2%) 40% 0 5%
Sadowi58 Poland (1996–2005) Ca, Ninv, Ainv 114 17% (13%) 18% 14% 12% (9–2%) 37% 1% 1%
Huber59 Kenya (2007–2010) Ca, Ainv 169 12% (9%) 17% 21% 14% (5%–4%) 27% 2% 7%
Brochet7 Dakar Bangui (2006–2007) Ca 163 20% (9%) 6% 12% 28% (4%–15%) 17% 15% 2%
NA, Not available.
*As percentage in each clonal complex.
wFirst author of the publication and reference.
zIn parenthesis the years of isolation if known.
yThe epidemiological origin: Ca, carriage, Ninv, neonatal invasive disease, Ainv, adults invasive disease.
||In parenthesis, the percentage corresponding to the indicated sequence types (STs).
zCorresponds to strains from the closely related clonal complexes (CC) CC6, CC8 and CC10.
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of SNPs, since their respective last common ancestor ranging
from 74 to 174 SNPs per Mb. To date the last common ancestor
of these clusters and of the nodes corresponding to the major sub-
lineages, we performed temporal Bayesian analyses (BEAST)12 of
CC1, CC17, CC19 and CC23 for which the number of isolates
and the timespan of isolations provided sufficient posterior
support (Fig. 1b–e). This analysis estimated that these CCs
emerged from a common ancestor within the last 300 years, at a
mutation rate of 0.56–0.93 SNP per Mb per year (Fig. 1b–e;
Table 2). These values are in-between the mutation rate predicted
for the hypervirulent 027/BI/NAP1 Clostridium difficile variant
(0.15–0.53 mutations per year per Mb)13 and for the globally
expanded multidrug-resistant PMEN1 pneumococcus (1.57
mutations per year per Mb)14. Nevertheless, the diversification
of the six CCs predates by several decades the clinical emergence
of GBS neonatal infections that took place in the 1960s3;
therefore, the increased incidence of neonatal infections cannot
be directly connected to the selection of these clones. Conversely,
the majority of the predominant subclones within CC1, CC17,
CC19 and CC23, were predicted to have emerged between 1917
and 1966 (Fig. 1b–e), a time period corresponding to the observed
emergence of neonatal GBS infections. Linear regression of
maximum likelihood root-to-tip distances against the year of
sampling showed a strong correlation with this data (Fig. 5). This
temporal analysis indicates that an evolutionary bottleneck has
played a major role in altering the population structure of human
GBS within the mid-20th century.
Human GBS isolates belong mainly to a small number of TcR
clones. A striking feature of human GBS strains is their high rate
(490%) of TcR, which is predominantly linked with the tet(M)
gene encoding an elongation factor G-like protein. Among recent
GBS studies, tet(M) was found in 95% of human isolates in
Romania15, 85% in Kuwait16 and 91% in Tunisia17. In contrast,
tet(M)-associated TcR is much less frequent among strains of
bovine origin. Specifically, 58% of animal GBS isolates from
Portugal were TcR with only 22% expressing tet(M)18. Similar
observations have been made in France where 39% are TcR and
21% express tet(M)19, Estonia, where 22% of strains exhibited
varying levels of TcR20 and in GBS strains isolated from milk in
the state of New York where only 14.5% were TcR and 2.5%
expressed tet(M)21. Furthermore, the tet(M) gene was detected in
only 25% of the 51 bovine GBS genome sequences and 10% of the
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Figure 1 | Population structure of human GBS is driven by tetracycline resistance acquisition. (a) Whole-genome-based phylogeny of 229
sequenced GBS isolates and strain SS1219 isolated from fish48. Maximum Likelihood (ML) using MEGA was used to infer phylogenetic relationships.
The major clonal complexes (CC) 1, 10, 17, 19, 23 and 26 as defined on the GBS MLST web site (http://pubmlst.org/sagalactiae/) correspond to
well-defined branches. Isolates are indicated by dots coloured according to their geographical origin. Flanking the whole-genome phylogeny, are four
Bayesian maximum clade credibility phylogenies (b–e) based on the non-recombinogenic genome for the GBS CC17 (b), CC23 (c), CC19 (d) and CC1
strains (e). Divergence dates (median estimates with 95% highest posterior density dates in brackets) are provided in blue for the major nodes. Coloured
branches relate to the major tetracycline-resistant clones. Arrows indicate the predicted time of insertion of the ICE carrying the tet(M) resistance
determinant within the major clones. Capsular serotypes are indicated on the right of each tree according to the indicated colour code.
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genome of 22 GBS strains isolated from fish that were available at
the NCBI database as of 15 May, 2014. These values highlight a
very high incidence of tet(M)-associated TcR within human
isolates compared with animal GBS. It is known that the use of
antibiotics results in a strong positive selection for antibiotic-
resistant clones and an overall reduction in bacterial population
diversity22. To identify a possible link between the population
structure of human GBS and antibiotic resistance, we analysed
the resistome of the 229 sequenced genomes (Table 3). In
agreement with the epidemiological surveys, the most frequent
determinants in the 216 human isolates were tet(M) (n¼ 183,
84%) and tet(O) (n¼ 10, 5%) both encoding ribosomal protection
proteins, and erm(B) (n¼ 18, 9%) and erm(TR) (n¼ 12, 5.5%)
encoding methylases conferring resistance to macrolides and
lincosamides. Other resistance determinants were rare (Table 3).
Except for one strain, tet(M) was carried by two related
integrative and conjugative elements (ICEs): Tn916 (n¼ 111) or
Tn5801 (n¼ 70) (Fig. 3b). In the collection sequenced, Tn916 and
Tn5801 were found in 23 and 2 different insertion sites,
respectively (Table 4 and Supplementary Table 1). Importantly,
the expanded clones in all six CCs represent monophyletic
lineages sharing the TcR-conferring ICE inserted at the same
position (Table 4; Supplementary Table 1; Figs 3a and 4a and
Supplementary Figs 2–5). Moreover, for a given TcR lineage, each
transposon shows a maximum of five SNPs supporting a single
insertion event for each lineage. These data strongly suggest that
the acquisition of ICE harbouring tet(M) has been a landmark
event in the expansion of these lineages and in the emergence of
the human pathogenic GBS population. Tetracycline was first
used in 1948 therefore the subsequent expansion of TcR GBS
clones is in agreement with our temporal analysis dating the
origin of these clones in the mid-20th century (Fig. 1b–e).
Interestingly, the major clones include strains from different
European and African countries and from Australia, indicating
that following their selection, these clones spread globally.
GBS genomes contain a large number of ICEs and other
integrative elements. To determine whether the acquisition of
other genomic islands has also contributed to the expansion of
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Figure 2 | Distribution of SNPs and recombination across all GBS isolates from the six major CCs. The maps were generated by using the
SyntView software. Isolates were ordered according to the distance from the reference genome depicted at the inner circle. CC numbers are
indicated in the centre. Recombined regions compared with the reference genome correspond to regions with a higher density of SNPs indicated by
short lines on each circle corresponding to one strain. Around the outside circle are the relative positions of selected antigenic loci. The reference
genomes were BG-NI-011 for CC1, DK-NI-008 for CC10, COH1 for CC17, RBH11 for CC19, CCH210801006 for CC23 and Bangui-IP-105 for CC26.
Table 2 | Diversity within the six clonal complexes.
CC1 CC10 CC17 CC19 CC23 CC26
Strain name BG-NI-011 DK-NI-008 COH1 RBH11 CCH210801006 Bangui-IP-105
Genome size* 2,078 (25) 2,080 (34) 2,065 (1) 2,180 (34) 2,055 (17) 2,054 (45)
No. of isolates 39 18 79 39 36 6
Interrogated regionsw 914 kb 1,069 kb 1,860 kb 1,427 kb 980 kb 1,582 kb
Polymorphic positions 1,244 971 3,922 2,016 1,329 263
Recombinationz 987 kb
pil1, pil2, cps, R5,
alp, srr
914 kb
pil1, pil2, cps, R5,
alp, srr
68 kb
cps, R5
532 kb
cps, R5, pil2,
srr, alp
875 kb
pil1, pil2, cps, R5,
alp, srr
398 kb
Tn916/CRISPR,
R5, alp
Depthy 174±23 126±7 129±16 97±21 169±16 74±34
Mutation rate|| 0.64 — 0.56 0.93 0.75 —
*Total contig size in kb, in parenthesis, the number of contigs.
wCumulative size in kb of regions not predicted to have recombined.
zCumulative size in kb of the recombined regions and the exchanged antigenic loci.
yExpressed as the average number of single-nucleotide polymorphism (SNP) per Mb from the root to the tips of the tree for strains isolated after 2005.
||As estimated by dividing the depth of each lineage by its age predicted by the BEAST analysis, in SNPs per Mb per year (Fig. 1b–e).
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these clones, we systematically searched for genes specifically
acquired by the four major TcR lineages to which the reference
genomes belong (CC1 lineage Tn916-1, CC17 Tn5801-11, CC19
Tn916-17 and CC23 Tn5801-23). However, we did not find
evidence based on the sequenced genomes that such events have
taken place.
Macrolide resistance contributed to CC1 expansion. Tetra-
cycline is not used to treat GBS infections; the most commonly
employed antibiotics are -lactams, followed by macrolides23.
Several epidemiological studies reported an increase in the
incidence of macrolide resistance in GBS, in particular in
strains belonging to the CC1 (ref. 24). Indeed, among the 32
isolates of our collection that contained an erm gene, 19 belonged
to CC1 (50% of the sequenced CC1 collection) whereas the
remaining 13 were sporadically distributed among the other CCs
(Table 3). Among the 19 erm-positive CC1 isolates, 17 clustered
into three lineages nested into TcR lineages (Fig. 4a). In the
largest of these three lineages (n¼ 11 isolates), the erm(B) gene is
carried by Tn917 inserted into Tn916 leading to Tn3872 first
described in S. pneumoniae25. A twelfth isolate, Bangui-IP-50,
which belongs to another sub-lineage of the CC1 Tn916-1 lineage,
also carries a Tn3872 element. Comparison of the ancestral Tn916
and the two versions of Tn3872 showed that the majority of the
SNPs (12 out of 15, strain DE-NI-001 and the 76 SNPs, strain
Bangui-IP-50) clusters upstream of Tn917 (Fig. 4b). This
observation suggests that Tn917 was inserted in Tn916 by
recombination following the conjugative transfer of two versions
of Tn3872; however, we cannot rule out an integration of Tn3872
following the loss of Tn916. In S. agalactiae, Tn3872 was first
identified in four serotype V isolates and one serotype Ia isolate
showing similar macro restriction patterns26. The erm(B)
sequences in these strains are identical to the one present in the
major macrolide resistance sub-lineage we have identified, but
shows three SNPs over 738 bp in comparison with the Bangui-IP-
50 erm(B) gene. Furthermore, the insertion site reported for
Tn3872 is the same as the insertion site of Tn916-1. It is therefore
likely that the four serotype V isolates carrying Tn3872 previously
described belong to this sub-lineage. These findings show that the
erm genes were gained after the acquisition of Tn916. Therefore,
acquisition of macrolide and lincosamide resistance genes
occurred after the selection of the TcR clones, and in the case
of the ST1 Tn916-1 lineage, has contributed to its clonal
expansion.
Discussion
Our analyses indicate that the observed emergence of GBS
infections in the 1960s was not due to past under-diagnosis and
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Figure 3 | Phylogeny of the ‘hypervirulent’ CC17 lineage. (a) ML phylogeny based on the alignment of 3,922 polymorphic positions. Six independent ICE
insertions (indicated on the right and by blue arrows) corresponding to six different lineages (indicated by different colours) were identified and are
numbered from 11 to 16 (Table 4). A star indicates that Tn5801 has been lost by this isolate. Following the loss of Tn5801, strains CCH210160764 and
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coloured in yellow, genes encoding type 4 secretion system components are in blue and the integrase and excisionase genes which are not conserved
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case reporting of the disease27 but that it corresponds to a
dramatic modification of the human GBS population. Indeed, we
show that the human disease-causing and carriage GBS
population is dominated be few TcR clones that have spread
globally. Tetracycline is a broad-spectrum antibiotic, which was
first used clinically in 1948. Subsequently it became widely used,
with the first reported case of TcR described in Shigella
dysenteriae in Japan in 1953 (ref. 28). This timeframe is
compatible with the Bayesian estimates that predicted the
origin of the GBS TcR clones in four CCs in the mid-20th
century (Fig. 1b–e) and the identification of three TcR isolates
dating back to 1955 within the CC17 clone carrying Tn916-12.
These three isolates represent the oldest known strains carrying
Tn916 (ref. 29). Strikingly, unlike non-CC17 isolates, and despite
the larger number of sequenced isolates (n¼ 79), all CC17 strains
belong to clones that have acquired Tn916 or Tn5801 (Fig. 3a and
Table 4). The absence of a CC17 population naive for these ICEs
suggests that CC17 strains were rare before the evolutionary
bottleneck exerted by the widespread use of tetracycline. Thus,
our data allow us to propose that the acquisition of TcR led to the
expansion of hypervirulent CC17 clones that then contributed to
the increase of neonatal infections.
Due to the broad distribution of resistance in many bacterial
species, the use of tetracycline in human health has declined30.
However, in contrast to what is usually observed for other
bacterial species when antibiotic selection pressure decreases, TcR
among human GBS remains remarkably stable at the same very
high level (490%). These observations suggest that once inserted
in the GBS genome, Tn916 and Tn5801 are maintained, as they
seem to impose a limited fitness cost to GBS. Indeed, it has been
suggested that due to the intricate mechanism of Tn916
regulation, Tn916 gene expression likely results in minimizing
the biological cost to the host31,32. It should be noted that the
dominance of the tet(M) gene carried by these ICEs is not specific
to GBS31. Indeed, 133 of 271 Enterococcus faecalis genome
sequences available in GenBank as of 15 May, 2014 contain a
tet(M) gene, while only 11 contain tet(S) and one tet(O).
Furthermore, TcR genes remain the most abundant antibiotic
resistance genes identified in human gut microbiota as recently
reported33. Therefore, the strong selective pressure that
tetracycline usage has exerted is more widely observed, but in
the case of GBS it has led to the emergence of pathogenic clones.
Recombination through the conjugative transfer of large
genomic regions has a major role in the diversification of GBS
lineages (Fig. 2). In particular, serotype switching due to
recombination of the chromosomal region encompassing the
capsular biosynthesis locus is the event the most frequently
observed. This is also supported by overlaying the capsular
serotype distribution onto the Bayesian phylogeny (Fig. 1b–e).
Indeed, the majority of strains within CC1, CC17, CC19 and
CC23 cluster into a dominant capsular serotype (cps): CC1/cpsV,
CC17/cpsIII, CC19/cpsIII and CC23/cpsIa. However, there is a
still substantial heterogeneity within CCs relating to capsular
serotype. In the case of CC19 and CC23, capsular switching is
evident within the major TcR clone. Like the other major CCs
examined in this study, isolates belonging to CC17 share a recent
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Figure 4 | Phylogeny of clonal complex CC1. (a) ML phylogeny from the alignment of pseudosequences of the 1,244 polymorphic positions in 914
interrogated kbases. The five independent Tn916 or Tn5801 insertions are indicated in blue and numbers from 1 to 5 refer to their description in Table 4.
The two TcR lineages with more than one isolate are coloured in blue and red. Three sub-lineages have acquired an erm resistance gene. Within
lineage Tn916-1, 40% of the isolates (12) carry Tn3872 (dark-blue branch and strain Bangui-IP-30). The four observed serotypes (cps) II, IV, V and VI are
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origin, however, they differ from the other CCs by a low rate of
recombination. Indeed, in this CC, we detected only two
recombination events in the early branch leading to the serotype
IV ST256 sub-lineage (Table 2). No recombination was identified
among CC17 strains, although we have previously shown that,
under laboratory conditions, these strains are as permissive to
conjugative transfers and recombination as non-CC17 strains10.
Furthermore, all CC17 strains encode a specific repertoire of
surface proteins shown to contribute to increased adherence to
intestinal, choroid plexus and microvascular endothelial cells6.
These observations suggest that CC17 strains colonize a specific
habitat leading to genetic isolation.
In GBS, the vast majority of Tn916 and Tn5801 are inserted in
the core genome (Table 4). Therefore, these ICE were acquired by
conjugation and tet(M) is likely the major adaptive function not
directly associated with genes encoding virulence factors as it has
been described in enterococci34. However, the expansion of these
TcR clones does not explain the concurrent emergence of
neonatal infections. We propose as a model that among the
selected TcR clones, those with a higher potency to colonize and
to disseminate have been selected and have spread across
continents replacing less virulent clones. The higher rate of TcR
strains and more particularly of the tet(M) gene in human
compared with bovine isolates is in support of this hypothesis.
70
56
42
28
14
54
40.5
27
13.5
68.8
51.6
34.4
17.2
54
40.5
27
13.5
1970 1980 1990 2000 2010
Time
1970 1980 1990 2000 2010
Time
13.3
26.6
39.9
53.2
66.5
CC23
r 2= 0.002
CC17-2
r 2= 0.5
CC1
r 2= 0.2
CC17-2
r 2= 0.41
CC19
r 2= 0.02
1700 18001600 1900 2000
Time
1930 1950 1970 1990 2010
Time
1930 1950 1970 1990 2010
Time
Figure 5 | Correlation of isolation date with maximum likelihood root-to-tip branch length for the five major TcR lineages calculated with
Path-O-Gen. These analyses predict the origin of these clones in agreement with the BEAST analysis except for the CC23 lineage where there was
a lack of temporal sampling to support tree root estimates. X axis, time in years; Y axis root-to-tip branch length in SNP per Mb. (a) CC1 lineage Tn916-1;
(b) CC19 lineage Tn916-17; (c) CC17 lineage Tn5801-11; (d) CC17 lineage Tn916-12; (e) CC23 lineage Tn5801-23.
Table 3 | Distribution of antibiotic resistance genes among the 229 sequenced isolates.
Antibiotic resistance Gene Number of isolates Total
CC1 CC10 CC17 CC19 CC23 CC26 Other
Tetracycline tet(M) 34 13 77 27 27 5 7 190
tet(O) 1 2 1 6 1 0 0 11
tet(L) 0 1 0 0 1 2 0 4
Erythromycin erm(B) 13 0 2 4 0 0 0 19
erm(TR) 6 0 0 2 2 2 0 12
erm(T) 0 1 0 0 0 0 0 1
mefE 0 0 0 0 1 0 0 1
Streptomycin aadE 1 0 0 4 1 0 0 6
Kanamycin aph30-III 0 0 0 3 1 0 0 4
Streptothrycin sta 0 0 0 3 1 0 0 4
Chloramphenicol cat 0 0 0 2 0 0 0 2
Lincosamides lnuB 0 0 0 1 0 0 0 1
Lincosamide—streptogramin lsa(C) 1 1 0 2 1 0 1 6
Spectinomycin spcR 3 0 0 2 1 2 0 8
Total number of isolates 39 19 78 39 36 6 12 229
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A link between antibiotic resistance and increased virulence or
transmissibility has been observed for different lineages of
opportunistic pathogens leading to the concept of ‘superbugs’35.
Examples are the C. difficile clone 027/BI/NAP1, among which
two highly virulent lineages expanded following the independent
acquisition of resistance to fluoroquinolones13, and the epidemic
community-acquired methicillin-resistant Staphylococcus aureus
clone USA300, which is more virulent than hospital acquired
MRSAs, and which emerged from CC8 S. aureus following the
acquisition of the methicillin resistance-encoding staphylococcal
cassette chromosome mec (SCCmec) type IV element, and the
arginine catabolite mobile element36. In USA300, the type I
arginine catabolite mobile element is integrated proximal to the
SCCmec element, and carries a speG gene which encodes a
spermidine acetyl transferase that has been shown to contribute
to the dissemination and to the virulence of these strains37.
Another striking example is the Enterococcus faecium hospital-
associated lineages ST17, ST18 and ST78 that are all virulent and
resistant to multiple antibiotics including vancomycin38,39.
E. faecium hospital-adapted lineages show a distinct genetic
repertoire compared with carriage strains and phylogenomic
analysis indicated that they are unrelated to human carrier
isolates but they originate from animal strains39. However,
unique to GBS, the recent evolutionary bottleneck due to the use
of tetracycline led to the global replacement of the GBS
population colonizing humans. In particular, this bottleneck led
to the fixation of the CC17 lineage, which shows a higher
virulence in neonates6. Therefore, our data strongly suggest that
the widespread use of tetracycline has helped drive the emergence
of GBS neonatal infections, and created pandemic drug-resistant
clones which pose a continued threat to human health.
Methods
Streptococcus agalactiae (GBS) isolates. GBS strains isolated between 1953
and 2011 are listed in Supplementary Table 1. Their geographical origin, the
epidemiological status (early-onset disease; late-onset disease; adult invasive
disease, AInv; neonatal invasive disease, NInv; carriage or of animal origin), the
year of isolation, the capsular serotype (cps) and the sequence type are indicated.
Strains were predominantly isolated from Europe (nine countries), Africa (three
countries) and Australia. Carriage and invasive strains were selected to reflect the
distribution of isolates according to MLST studies (Table 1). CC17 strains were
over represented in the collection in an attempt to help characterize the specificity
of this hypervirulent lineage. The 12 strains isolated between 1953 and 1961 from
Table 4 | Characteristics of clones deriving from Tn916 and Tn5801 insertions.
Clone No. of isolates per clone Integrative and conjugative element
and site* of insertion
Recombination events
within the clonew
N CC Sequence type cps
1 1 1 V 27 (2)z Tn916 GI 624 kby,,|| 92 kb alp; 100 kb
2 196, 459 IV 6 Tn916 GI 624 kby,,|| 80 kb alp: 35 kb
3 2 IV 1 Tn5801 972 kbz —#
4 2 IV 1 Tn5801 972 kbz n.a.
5 2 II 1 Tn916 726 kb n.a.
3** n.a.
6 10 10 V-II 5 Tn5801 972 kbz 347 kb cps operon
7 8 Ib 4 Tn916 846 kb —
8 12 II 1 Tn916 260 kb n.a.
9 10 Ib 1 Tn916 626 kb n.a.
10 10 II 2 Tn916 1,255 kb —
5** n.a.
11 17 17 III 42 (3)z Tn5801 972 kbz —
12 17 III 23 Tn916 241 kb —
13 17 III 6 Tn916 950 kb —
14 17 III 2 Tn916 1,928 kb —
15 17 III 1 Tn916 1,928 kb n.a.
16 291 IV 5 Tn5801 52 kb —
17 19 19 III V 20 (3)z Tn916 923 kb 253 kb cps operon 36 kb R5 protein
18 19 III 4 (1)z Tn916 GI 557 kb|| —
19 19 III 1 Tn916 2,005 kb n.a.
20 28 II 2 Tn916 395 kb —
21 28 II 3 Tn916 1,445 kb —
22 28 II 1 Tn916 2,005 kb n.a.
8** n.a.
23 23 23 Ia 18 (1)z Tn5801 972 kbz 107 kb alp; 56 kb R5 protein; 93 kb
24 23, 144 Ia–V 8 (1)z Tn916 1,928 kb 91 kb alp; 193 kb cps
25 23 III 1 Tn5801 972 kbz n.a.
26 23 Ia 1 Tn5801 972 kbz n.a.
8** n.a.
27 26 26 V 3 Tn916 GI 1,023 kb|| —
28 26 V 2 Tn916 923 kb 77 kb R5 protein
29 22 22 II 2 Tn916 1787 kb —
n.a., Not applicable.
*Position relative to the completely sequenced 2603 V/R genome45.
wSize of the recombined regions and antigenic loci.
zIn parenthesis are indicated the number of strains predicted to have lost Tn916 or Tn5801.
yTn916 is inserted in the opposite orientation at the same site.
||Tn916 is inserted within genomic islands inserted at the reported locations relative to the 2603 V/R genome.
z972 kb correspond to a hot spot of insertion of Tn5801 at the 5’ end of the guaA gene.
#A dash indicates no recombination event.
**Number of isolates in clonal complex (CC)1, 10, 19 and 23 predicted not to have acquired Tn916 or Tn5801.
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the Institut Pasteur bacterial strain collection (CRBIP) belong to CC17, CC19
and CC23. The earliest isolates from the CC1 lineage are from 1997, therefore
contributing to lower confidence in dating the origin of this particular lineage
(Fig. 1e). Thirteen strains are of animal origin.
Sequencing, mapping and SNP detection. Genomes were sequenced using the
Illumina GAIIX or HiSeq2000 sequencing platforms. The read length for each
genome is specified in Supplementary Table 1. The minimal coverage was 75-fold.
The sequencing reads were filtered to exclude reads with a quality score ofo25 in
10% of the reads and aligned to the reference sequence by using Burrows-Wheeler
Aligner40. SNP calling was done using SAMtools MPILEUP and varFilter41.
We excluded SNPs identified in repeated regions, within 100 bp of the contig
boundaries from draft reference genome assemblies, or in regions with coverage
lower than 40% of the strain’s mean coverage. Reference genomes selected as
belonging to the dominant clone of each CC are described in Table 2. The genome
of strain COH1 was completely finished by closing the gaps of the previously
determined draft genome sequence42. Finishing was performed by Sanger
sequencing of PCR products corresponding to gaps and to low-quality regions.
The COH1 genome was annotated as previously described43. Briefly, coding
sequences were defined by combining Genmark predictions with visual inspection
of each open-reading frame for the presence of a start codon with an upstream
ribosome-binding site and BLASTp similarity searches on Uniref 90, Trembl and
Swissprot databases. Function predictions were based on blastp similarity searches
and on the analysis of motifs using the Pfam databases (http://pfam.xfam.org/).
The five other reference genomes were obtained after ordering the Velvet
assembled contigs by using the MAUVE software44 and the genome of 2603V/R as
reference45. They were automatically annotated by using the RAST server46.
De novo assembly and sequence analysis. Genome sequences were assembled
using the Velvet software47 with an optimized k-value and a minimal coverage of
10. MLST types were determined by extracting the sequences of the seven genes of
the GBS MLST system5 and comparing them with the known STs from the GBS
MLST web server (http://pubmlst.org/sagalactiae/). Serotypes were determined by
BLASTn similarity search using as query the nucleotide sequences of the ten cps
loci corresponding to the 10 known GBS serotypes. Antibiotic resistance genes
were searched by BLASTx search with the protein sequences of 38 resistance genes
from Gram-positive bacteria for tetracycline, macrolides, streptomycin, kanamycin,
spectinomycin, streptothrycin, lincosamides and chloramphenicol. Genomic
islands encoding antibiotic resistance genes were analysed by extracting the
sequences surrounding the antibiotic resistance genes. Tn916 and Tn5801 insertion
sites were determined by analysing the chromosome–transposon junctions
(Table 4).
Phylogenetic analysis. A phylogeny of the 229 GBS isolates sequenced here and
the fish isolate SS1219 (ref. 48) was constructed by considering nucleotides
corresponding to all variable positions located in the core genome for example, in
regions present in all isolates. Individual phylogenies of the six CCs were
performed after removal of the genomic islands not shared by all isolates, and
recombined regions. Automatic detection of recombined regions using the Gubbins
software14 was used to predict genome variation that had arisen by homologous
recombination. The ability of this method to robustly predict recombination across
the whole population was limited due to the observed genetic diversity of the
population, and the corresponding deep branches of the phylogeny. We therefore
combined this automatic detection with the visual inspection of variation in each of
individual CCs in SyntView49 viewer (http://genopole.pasteur.fr/SynTView/flash/
Streptococcus_agalactiae), to identify clusters of SNPs likely to have arisen by
recombination. Phylogenetic relationships were inferred using the Maximum
Likelihood (ML) method in MEGA5 version 5.10 (ref. 50) and the BEAST software
v1.7.5 (ref. 51). The confidence of the ML tree was estimated using the bootstrap
method with 200 bootstrap replications. The trees of the six individual CCs were
rooted by using the sequence of an isolate belonging to another CC. The species
tree is unrooted. The Bayesian phylogenetic software of BEAST v1.7.5 (ref. 12) was
used to investigate the temporal evolution of CC1, CC17, CC19 and CC23. The
non-recombined variable sites as defined above for each CC was used as markers of
ancestral polymorphisms and the year of isolation for each isolate (Supplementary
Table 1) was used to calibrate the clock rate. We used the GTR model of nucleotide
substitution with four discrete gamma-distributed rate categories and a default
gamma prior distribution of 1. To identify the most suitable models, we compared
the strict, lognormal relaxed and exponential-relaxed molecular clock models and
coalescent constant, exponential growth, expansion growth and Bayesian skyline
tree models, using stepping-stone sampling and comparison of log marginal
likelihoods52–54. Model analyses were conducted in triplicate for 50 million Markov
Chain Monte Carlo generations with samples taken every 1,000 generations.
Replicate analyses were combined with 10% removed as burn-in using
LogCombiner12. The Bayesian skyline tree model along with the uncorrelated
lognormal relaxed molecular clock to accommodate for rate variation among
lineages was preferred. Therefore, final phylogenetic analyses were run in triplicate
for 100 million Markov Chain Monte Carlo generations with 10% burn-in using
the above parameters. Overall congruency of Bayesian models were observed for all
four CCs analysed by BEAST; however, the lack of a wide temporal sampling of
strains for CC1 resulted in the lack of an accurate root to accurately define a clock
rate, hence the broad confidence values observed in Fig. 1e. Path-O-Gen (http://
tree.bio.ed.ac.uk/software/pathogen/) was used to identify a ‘molecular clock’
evolutionary signal as defined by a linear association between the ML root-to-tip
branch lengths and year of strain isolation for the five major TcR sub-lineages. This
also enabled an alternative method to the Bayesian approach of BEAST to date the
expansion event of the five major TcR sub-lineages. ML trees were generated in the
sub-lineages: CC1 Tn916-1 (n¼ 26); CC19 Tn916-17 (n¼ 20); CC17 Tn5801-11
(n¼ 41); CC17 Tn916-12 (n¼ 23) and CC23 Tn5801-2 (n¼ 18) from the same
recombination-removed SNP alignments used for BEAST analyses.
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